Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against Ankylosing spondylitis

Iranian Journal of Immunology

Volumn 7, Issue 2, 2010, Pages 88-95

  Mousavi, Tahereh ^a   Poormoghim, Hadi ^a   Moradi, Maziar ^a   Tajik, Nader ^a   Shahsavar, Farhad ^b   Asadifar, Behnam ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ankylosing spondylitis; CD56; HLA; KIR3DL1

Indexed keywords

ASPARAGINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; LYMPHOCYTE ANTIGEN; LYSINE; UNCLASSIFIED DRUG; CD56 ANTIGEN; HLA BW4; HLA-BW4; KIR2DL1 PROTEIN, HUMAN; KIR2DL2 PROTEIN, HUMAN; KIR2DS4 PROTEIN, HUMAN; KIR3DL1 PROTEIN, HUMAN;

ALLELE; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FLOW CYTOMETRY; GENE FREQUENCY; HLA B GENE; HUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; DOWN REGULATION; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PATHOPHYSIOLOGY;

ANTIGENS, CD56; DOWN-REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR; RECEPTORS, KIR2DL1; RECEPTORS, KIR2DL2; RECEPTORS, KIR3DL1; SPONDYLITIS, ANKYLOSING;

EID: 79952288662     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Shamji MF, Bafaquh M, Tsai E. The pathogenesis of ankylosing spondylitis. Neurosurg Focus 2008; 24:E3.
2. Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT, et al. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia. Arthritis Rheum. 2007; 56:2640-51.
3. Tsuchiya N, Kyogoku C, Miyashita R, Kuroki K. Diversity of human immune system multigen families and its implication in the genetic background of rheumatic diseases. Curr Med Chem. 2007; 14:431-9.
4. Kollnberger S, Bird L.A, Roddis M, Hacquard-Bouder C, Kubagawa h, Bodmer H.C, et al. HLA-B27 Heavy Chain Homodimers Are Expressed in HLA-B27 Transgenic Rodent Models of Spondyloarthritis and are Ligands for Paired Ig-Like Receptors. J.Immunol. 2004;173:1699-710.
5. Jiao YL, Ma CY, Wang LC, Cui B, Zhang J, You L, et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol. 2008; 28:343-9.
6. Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J. Hepatol. 2007; 46:899-906.
7. Parham P. MHC class I molecules and KIRs in human history, Health and survival. Nat Rev. Immunol. 2005; 5:201-14.
8. Yawata M, Yawata N, Draghi M, Little A, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med,.2006; 203:633-45.
9. Wendling D, Racadot E, Guidet M. Natural cytotoxic function and ankylosing spondylitis. Pathol Biol (Paris). 1989; 37:888-92.
10. Jiao Y, Ma CY, Wang LC, Cui B, Zhang J, You L. Polymorphisms of KIRs Gene and HLA-C Alleles in Patients with Anky-losing Spondylitis: Possible Association with Susceptibility to the Disease J Clin Immunol. 2008; 28:343-9
11. Niokou D, Spyropoulou-Vlachou M, Darlamitsou A, Stavropoulos-Giokas C. Distribution of Killer Cell Immunoglobulin-like Receptors in the Greek Population. Hum Immunol. 2003; 64:1167-76.
12. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 2009; 60:1753-63.
13. Azuz-Lieberman N, Markel G, Mizrahi S, Gazit R, Hanna J, Achdout H, et al. The involvement of NK cells in ankylosing spondylitis. Int Immunol. 2005 Jul; 17:837-45
14. Wendling D, Racadot E, Guidet M. Natural killer cell function and ankylosing spondylarthritis. Rev Rhum Mal Osteoartic. 1989; 56:51-2.
15. Johansson S, Hall H, Berg L, Höglund P. NK cells in autoimmune disease. Curr Top Microbial Immunol. 2006; 298:259-77.
16. Szántó S, Aleksza M, Mihály E, Lakos G, Szabó Z, Végvári A, et al. Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis. J. Rheumatol. 2008; 35:2372-5.
17. Lassoued S, Roubinet F, Hamidou M, Kuhlein E, Cassar G, Fournie B, et al. Large granular lymphocytes and neutropenia in a patient with ankylosing spondylitis. Arthritis Rheum. 1989; 32:355.
18. Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD. KIRs and autoimmune disease. Tissue Antigens. 2007; 69:106-8.
19. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994; 21:2281-5.
20. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylos- ing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21:2286-91.
21. Middleton D, Meenagh A, Wright GD. No association in frequency of KIR receptors in patients with rheumatoid arthritis from Northern Ireland. Tissue Antigens. 2007; 69,577-82.
22. Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. The protein made from a common allele of KIR3DL1(3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol. 2003; 171: 6640-9.
23. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005; 175: 5222-9.
24. Díaz-Peña R, Vidal-Castiñeira JR, Alonso-Arias R, Vicario JL, Solana R, Collantes E, et al. Association of KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum. 2010; 62:1000-6
25. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. immunol. 2007; 178:235-41.
26. Sanjanwala B, Draghi M, Norman PJ, Guethlein LA, Parham P. polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIRDL1. J. immunol. 2008; 181:6293-300.
27. Morvan M, Willem C, Gogane K, Kerdudou N, David G, Sebille V, et al. phenotypic and functional analysis of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J. Immunol. 2009; 182:6727-35.
28. Williams F, Meenagh A, Sleator C, Cook D, Fernandez-Vina M, Bowcock AM, Middleton D. Activating Killer Cell Immu- noglobulin-Like Receptor Gene KIR2DS1 Is Associated With Psoriatic Arthritis. Human Immunology. 2005; 66:836-41.